已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Analysis of upfront resection or stereotactic radiosurgery for local control of solid and cystic cerebellar hemangioblastomas

医学 放射外科 血管母细胞瘤 单变量分析 外科 肿瘤进展 回顾性队列研究 多元分析 放射科 癌症 放射治疗 内科学
作者
Luis R. Carrete,Ramin A. Morshed,Jacob S. Young,Lauro N. Avalos,Penny K. Sneed,Manish K. Aghi,Michael W. McDermott,Philip V. Theodosopoulos
出处
期刊:Journal of Neurosurgery [Journal of Neurosurgery Publishing Group]
卷期号:140 (2): 404-411 被引量:2
标识
DOI:10.3171/2023.6.jns222629
摘要

OBJECTIVE The purpose of this study was to identify rates of and risk factors for local tumor progression in patients who had undergone surgery or radiosurgery for the management of cerebellar hemangioblastoma and to describe treatments pursued following tumor progression. METHODS The authors conducted a retrospective single-center review of patients who had undergone treatment of a cerebellar hemangioblastoma with either surgery or stereotactic radiosurgery (SRS) between 1996 and 2019. Univariate and multivariate regression analyses were performed to examine factors associated with local tumor control. RESULTS One hundred nine patients met the study inclusion criteria. Overall, these patients had a total of 577 hemangioblastomas, 229 of which were located in the cerebellum. The surgical and SRS cohorts consisted of 106 and 123 cerebellar hemangioblastomas, respectively. For patients undergoing surgery, tumors were treated with subtotal resection and gross-total resection in 5.7% and 94.3% of cases, respectively. For patients receiving SRS, the mean target volume was 0.71 cm 3 and the mean margin dose was 18.0 Gy. Five-year freedom from lesion progression for the surgical and SRS groups was 99% and 82%, respectively. The surgical and SRS cohorts contained 32% versus 97% von Hippel–Lindau tumors, 78% versus 7% cystic hemangioblastomas, and 12.8- versus 0.56-cm 3 mean tumor volumes, respectively. On multivariate analysis, factors associated with local tumor progression in the SRS group included older patient age (HR 1.06, 95% CI 1.03–1.09, p < 0.001) and a cystic component (HR 9.0, 95% CI 2.03–32.0, p = 0.001). Repeat SRS as salvage therapy was used more often for smaller tumor recurrences, and no tumor recurrences of < 1.0 cm 3 required additional salvage surgery following repeat SRS. CONCLUSIONS Both surgery and SRS achieve high rates of local control of hemangioblastomas. Age and cystic features are associated with local progression after SRS treatment for cerebellar hemangioblastomas. In cases of local tumor recurrence, salvage surgery and repeat SRS are valid forms of treatment to achieve local tumor control, although resection may be preferable for larger recurrences.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yuyu发布了新的文献求助200
刚刚
Breez2004发布了新的文献求助10
刚刚
神兽下山完成签到,获得积分10
2秒前
上官若男应助福缘采纳,获得10
2秒前
3秒前
5秒前
阿鑫发布了新的文献求助10
7秒前
7秒前
小武同学完成签到 ,获得积分10
7秒前
8秒前
清澈的爱只为中国完成签到 ,获得积分10
9秒前
TY发布了新的文献求助10
10秒前
10秒前
11秒前
闻所谓闻发布了新的文献求助10
12秒前
liu完成签到,获得积分10
13秒前
橘子柚子完成签到 ,获得积分10
14秒前
Lynne发布了新的文献求助10
14秒前
斯文败类应助踏实的紫安采纳,获得10
15秒前
15秒前
15秒前
16秒前
17秒前
18秒前
自觉的鲂完成签到,获得积分10
18秒前
嘿嘿发布了新的文献求助10
19秒前
666发布了新的文献求助30
19秒前
20秒前
同行完成签到 ,获得积分10
21秒前
小赵完成签到,获得积分10
23秒前
无畏山海发布了新的文献求助10
23秒前
风清扬发布了新的文献求助10
24秒前
24秒前
Kkitora发布了新的文献求助10
27秒前
RLV发布了新的文献求助10
27秒前
28秒前
30秒前
32秒前
34秒前
阳光的海露完成签到,获得积分10
35秒前
高分求助中
2025-2031全球及中国金刚石触媒粉行业研究及十五五规划分析报告 25000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1000
The Composition and Relative Chronology of Dynasties 16 and 17 in Egypt 1000
Russian Foreign Policy: Change and Continuity 800
Real World Research, 5th Edition 800
Qualitative Data Analysis with NVivo By Jenine Beekhuyzen, Pat Bazeley · 2024 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5705304
求助须知:如何正确求助?哪些是违规求助? 5162660
关于积分的说明 15244765
捐赠科研通 4859189
什么是DOI,文献DOI怎么找? 2607598
邀请新用户注册赠送积分活动 1558753
关于科研通互助平台的介绍 1516319